Be a PRO & get up to 50% off on select brands. Explore Now
you are here: HomeNewsBusiness

Buy Laurus Labs; target of Rs 440: ICICI Direct

ICICI Direct is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 440 in its research report dated January 30, 2021.

February 05, 2021 / 07:14 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Laurus Labs

Q3 revenues grew ~76.6% to Rs 1288 crore amid strong growth across segments driven by 103.5% YoY jump in API segment to Rs 731 crore amid strong traction in antiviral APIs to Rs 568 crore (2.65x YoY) driven by higher volume of first-line products. Formulations revenue grew 47.2% YoY to Rs 430 crore on the back of higher tender business from LMIC and higher volumes from US, Europe. CRAMS business grew 62.4% YoY to Rs 127 crore. EBITDA margins improved 1278 bps to 33.1% due to better product mix and improved operating leverage. Subsequently, EBITDA grew 187.7% YoY to Rs 426 crore. PAT was up 271.3% YoY at Rs 273 crore.


We maintain BUY rating with a target price of Rs 440 (vs. Rs 390 earlier) based on 18x of FY23E EPS of 24.4.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Feb 5, 2021 07:14 pm

stay updated

Get Daily News on your Browser